Onpattro, Tegsedi Cardiac Imaging And Serum Biomarker Data Failed To Impress US FDA

 
• By Sue Sutter
  
Drug Review Profile regular column
For both Onpattro and Tegsedi, FDA reviewers recommended limiting the indications to hATTR patients with polyneuropathy.

More from Drug Review Profiles

More from Product Reviews